BG107547A - Фармацевтичен препарат за лечение и диагноза на тумори и метод за получаване на липидночиста фракция от кръвна плазма - Google Patents
Фармацевтичен препарат за лечение и диагноза на тумори и метод за получаване на липидночиста фракция от кръвна плазма Download PDFInfo
- Publication number
- BG107547A BG107547A BG107547A BG10754703A BG107547A BG 107547 A BG107547 A BG 107547A BG 107547 A BG107547 A BG 107547A BG 10754703 A BG10754703 A BG 10754703A BG 107547 A BG107547 A BG 107547A
- Authority
- BG
- Bulgaria
- Prior art keywords
- fraction
- lipid
- treatment
- blood
- tumor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 161
- 238000011282 treatment Methods 0.000 title claims abstract description 161
- 210000002381 plasma Anatomy 0.000 title claims abstract description 97
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims description 51
- 238000002360 preparation method Methods 0.000 title claims description 32
- 238000003745 diagnosis Methods 0.000 title claims description 6
- 150000002632 lipids Chemical class 0.000 title description 3
- 239000000463 material Substances 0.000 claims abstract description 112
- 210000004369 blood Anatomy 0.000 claims abstract description 82
- 239000008280 blood Substances 0.000 claims abstract description 82
- 241000283690 Bos taurus Species 0.000 claims abstract description 60
- 239000004094 surface-active agent Substances 0.000 claims abstract description 34
- 239000003960 organic solvent Substances 0.000 claims abstract description 30
- 238000005119 centrifugation Methods 0.000 claims abstract description 22
- 238000000926 separation method Methods 0.000 claims abstract description 21
- 239000007788 liquid Substances 0.000 claims abstract description 20
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 6
- 208000032839 leukemia Diseases 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 22
- 206010039491 Sarcoma Diseases 0.000 claims description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical group O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 210000003918 fraction a Anatomy 0.000 claims 4
- 231100001160 nonlethal Toxicity 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000011581 secondary neoplasm Diseases 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 1
- 238000009832 plasma treatment Methods 0.000 claims 1
- 238000001962 electrophoresis Methods 0.000 abstract description 7
- 241000283086 Equidae Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 92
- 238000002474 experimental method Methods 0.000 description 88
- 230000004083 survival effect Effects 0.000 description 86
- 241001465754 Metazoa Species 0.000 description 58
- 239000000306 component Substances 0.000 description 48
- 230000000694 effects Effects 0.000 description 42
- 239000013641 positive control Substances 0.000 description 36
- 238000010586 diagram Methods 0.000 description 23
- 230000006872 improvement Effects 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 238000002513 implantation Methods 0.000 description 18
- 102000004008 5'-Nucleotidase Human genes 0.000 description 14
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 14
- 230000001154 acute effect Effects 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 206010000830 Acute leukaemia Diseases 0.000 description 11
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 10
- 230000002349 favourable effect Effects 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 208000003747 lymphoid leukemia Diseases 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000001133 acceleration Effects 0.000 description 8
- 239000003599 detergent Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000894007 species Species 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 230000005741 malignant process Effects 0.000 description 4
- 230000004066 metabolic change Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 102000007132 Carboxyl and Carbamoyl Transferases Human genes 0.000 description 2
- 108010072957 Carboxyl and Carbamoyl Transferases Proteins 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 2
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010051925 Intestinal adenocarcinoma Diseases 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 108010002712 deoxyribonuclease II Proteins 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000292604 Salvia columbariae Species 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0002597A HUP0002597A2 (hu) | 2000-07-10 | 2000-07-10 | Gyógyászati készítmény, elsősorban tumoros megbetegedések gyógyítására és diagnosztizálására és eljárás vérplazma lipidmentes frakciójának előállítására |
| PCT/HU2001/000078 WO2002007739A2 (en) | 2000-07-10 | 2001-07-10 | Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG107547A true BG107547A (bg) | 2004-01-30 |
Family
ID=89978459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG107547A BG107547A (bg) | 2000-07-10 | 2003-02-10 | Фармацевтичен препарат за лечение и диагноза на тумори и метод за получаване на липидночиста фракция от кръвна плазма |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20040253317A1 (fi) |
| EP (1) | EP1333844A2 (fi) |
| JP (1) | JP2004504353A (fi) |
| KR (1) | KR20030016392A (fi) |
| CN (1) | CN1477965A (fi) |
| AU (1) | AU2001277630A1 (fi) |
| BG (1) | BG107547A (fi) |
| BR (1) | BR0112866A2 (fi) |
| CA (1) | CA2415862A1 (fi) |
| EA (1) | EA005415B1 (fi) |
| HR (1) | HRP20030098A2 (fi) |
| HU (1) | HUP0002597A2 (fi) |
| IL (1) | IL153867A0 (fi) |
| MX (1) | MXPA03000342A (fi) |
| PL (1) | PL361049A1 (fi) |
| SK (1) | SK1282003A3 (fi) |
| WO (1) | WO2002007739A2 (fi) |
| YU (1) | YU9903A (fi) |
| ZA (1) | ZA200300675B (fi) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0200172A2 (hu) | 2002-01-15 | 2003-11-28 | András Bertha | Eljárás tumorellenes hatóanyag kinyerésére |
| GB2405540B (en) * | 2003-08-27 | 2006-05-10 | Ron Shu-Yuen Hui | Apparatus and method for providing dimming control of lamps and electrical lighting systems |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB791142A (en) * | 1954-09-22 | 1958-02-26 | Atsuwo Ushiyama | A process for preparing antibiotic substance from special bacterium in human blood plasma and earth |
| GB834256A (en) * | 1955-08-18 | 1960-05-04 | Olin Mathieson | Therapeutic bone mixture |
| US3083194A (en) * | 1959-05-18 | 1963-03-26 | Thies Karl | Montmorillonite adsorption of fibrin from bovine blood plasma |
| JPS5357191A (en) * | 1976-11-04 | 1978-05-24 | Asahi Chem Ind Co Ltd | Activated carbon for adsorption of toxin in serum |
| NL9001087A (nl) * | 1990-05-07 | 1991-12-02 | Harimex Ligos Bv | Werkwijze voor het zuiveren van bloedplasma. |
| RO111332B1 (ro) * | 1991-06-17 | 1996-09-30 | Inst De Cercetari Chimico Farm | Procedeu de obținere a unui produs hepatoprotector |
| HUP9900045A3 (en) * | 1999-01-08 | 2001-02-28 | Martyn Robertne Goeroeg Jolan | Improved leukaemic blood-based product and their use in therapy |
-
2000
- 2000-07-10 HU HU0002597A patent/HUP0002597A2/hu unknown
-
2001
- 2001-07-10 CA CA002415862A patent/CA2415862A1/en not_active Abandoned
- 2001-07-10 EA EA200300133A patent/EA005415B1/ru not_active IP Right Cessation
- 2001-07-10 CN CNA018139744A patent/CN1477965A/zh active Pending
- 2001-07-10 PL PL01361049A patent/PL361049A1/xx unknown
- 2001-07-10 BR BRPI0112866 patent/BR0112866A2/pt not_active Application Discontinuation
- 2001-07-10 MX MXPA03000342A patent/MXPA03000342A/es unknown
- 2001-07-10 WO PCT/HU2001/000078 patent/WO2002007739A2/en not_active Application Discontinuation
- 2001-07-10 US US10/332,440 patent/US20040253317A1/en not_active Abandoned
- 2001-07-10 EP EP01955468A patent/EP1333844A2/en not_active Withdrawn
- 2001-07-10 JP JP2002513472A patent/JP2004504353A/ja active Pending
- 2001-07-10 AU AU2001277630A patent/AU2001277630A1/en not_active Abandoned
- 2001-07-10 IL IL15386701A patent/IL153867A0/xx unknown
- 2001-07-10 SK SK128-2003A patent/SK1282003A3/sk unknown
- 2001-07-10 KR KR10-2003-7000393A patent/KR20030016392A/ko not_active Application Discontinuation
- 2001-07-10 YU YU9903A patent/YU9903A/sh unknown
-
2003
- 2003-01-24 ZA ZA200300675A patent/ZA200300675B/xx unknown
- 2003-02-10 HR HR20030098A patent/HRP20030098A2/hr not_active Application Discontinuation
- 2003-02-10 BG BG107547A patent/BG107547A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2415862A1 (en) | 2002-01-31 |
| CN1477965A (zh) | 2004-02-25 |
| WO2002007739A2 (en) | 2002-01-31 |
| WO2002007739A9 (en) | 2003-10-16 |
| US20040253317A1 (en) | 2004-12-16 |
| KR20030016392A (ko) | 2003-02-26 |
| IL153867A0 (en) | 2003-07-31 |
| WO2002007739A3 (en) | 2002-10-10 |
| AU2001277630A1 (en) | 2002-02-05 |
| EP1333844A2 (en) | 2003-08-13 |
| SK1282003A3 (en) | 2003-08-05 |
| ZA200300675B (en) | 2004-02-19 |
| YU9903A (sh) | 2006-05-25 |
| JP2004504353A (ja) | 2004-02-12 |
| MXPA03000342A (es) | 2004-12-13 |
| HRP20030098A2 (en) | 2004-08-31 |
| EA200300133A1 (ru) | 2003-06-26 |
| HUP0002597A2 (hu) | 2003-01-28 |
| HU0002597D0 (en) | 2000-09-28 |
| EA005415B1 (ru) | 2005-02-24 |
| PL361049A1 (en) | 2004-09-20 |
| BR0112866A2 (fi) | 2009-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Edelson et al. | The immunologic function of skin | |
| JPH11501656A (ja) | 腫瘍を処置する方法 | |
| Delorme et al. | The cellular immune response to primary sarcomata in rats I. The significance of large basophilic cells in the thoracic duct lymph following antigenic challenge | |
| Youdim et al. | Thymus dependency of cells involved in transfer of delayed hypersensitivity to Listeria monocytogenes in mice | |
| US20140329322A1 (en) | Method of differentiating glioblastoma cells | |
| IE44378B1 (en) | Extracts of the haemopoietic system | |
| CN107119015B (zh) | 外泌体、其制备方法及其在制备治疗肺癌的药物中的应用 | |
| AU632999B2 (en) | Method and means for immuno-stimulating blood treatment with a mitogen | |
| BG107547A (bg) | Фармацевтичен препарат за лечение и диагноза на тумори и метод за получаване на липидночиста фракция от кръвна плазма | |
| Eckhardt et al. | K-lymphocytes (killer-cells) in Crohn's disease and acute virus B-hepatitis. | |
| Thorsby et al. | Lymphocytotoxic antisera of limited iso-specificity after skin grafting in man | |
| JP2000503631A (ja) | 非免疫原性かつ寛容原性の血小板組成物および赤血球組成物 | |
| WO2017003763A1 (en) | Methods of treating glioblastoma multiforme by t cell therapy | |
| RU2199327C2 (ru) | Очищенный регулятор роста клеток, способ его получения (варианты), способ лечения, профилактики и диагностики рака, состав для ингибирования роста клеток | |
| Dumonde | The Role of Lymphocytes and Macrophages in the Immunological Response: XIII International Congress of Haematology, Munich, August 2–8, 1970 | |
| JP3970916B2 (ja) | ナチュラルキラー細胞の増殖剤及び増殖方法 | |
| CA1333887C (en) | Immunity memory cell suspension and method of preparing same | |
| Goto et al. | Suppression of Hepatic Allograft Rejection in the Rat by Mitomycin C-Treated Donor Splenocytes: In SituSplenic Distribution of Donor Class I Major Histocompatibility Complex Antigen-Positive Cells in the Recipient | |
| AU2017210247A1 (en) | Methods and compositions for use in the prevention, treatment and/or alleviation of cancer | |
| CN117731687A (zh) | 枸杞功能多糖在制备免疫调节剂和抗肿瘤药物中的应用 | |
| JP2002521341A (ja) | 抗癌および抗炎症効果を有する牛糞抽出物およびその製造方法 | |
| EP3914070A1 (en) | Non-human animal models of sézary syndrome | |
| Thomson et al. | Comparison by leukocyte adherence inhibition of human immune response to cancer-associated immunogens, Thomsen-Friedenreich (T) and Tn, myelin basic protein, and organ-specific cancer neoantigens | |
| US20180021376A1 (en) | Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins | |
| SEYMOUR et al. | BONE MARROW TRANSPLANTS |